Which combination is recommended to support weight loss in type 2 diabetes?

Which combination is recommended to support weight loss in type 2 diabetes?

• A. GLP-1 analog or SGLT-2 inhibitors + metformin, with basal insulin if needed
• B. Metformin alone
• C. Sulfonylureas with insulin
• D. Thiazolidinediones with insulin

Answer: (A)

In weight management for type 2 diabetes, the most effective strategy blends glucose control with medications that help reduce or at least not increase body weight. A regimen that uses either a GLP-1 receptor agonist or an SGLT-2 inhibitor together with metformin fits this goal well. GLP-1 receptor agonists reduce appetite and slow stomach emptying, often leading to meaningful weight loss. SGLT-2 inhibitors promote urinary glucose excretion, which can also contribute to modest weight loss. Metformin, serving as a foundational therapy, is typically weight-neutral or can cause a small amount of weight loss and improves hepatic glucose production. If blood glucose remains above target after these agents, adding basal insulin can achieve better control, and when used carefully at low doses, it helps minimize additional weight gain. Other approaches are less favorable for weight loss. Metformin alone may control glucose but doesn’t provide the additional weight-loss benefits of GLP-1 RAs or SGLT-2 inhibitors. Sulfonylureas and insulin tend to promote weight gain and carry higher risks of hypoglycemia, and thiazolidinediones are associated with weight gain and fluid retention, making them less ideal if weight loss is a goal.

In weight management for type 2 diabetes, the most effective strategy blends glucose control with medications that help reduce or at least not increase body weight. A regimen that uses either a GLP-1 receptor agonist or an SGLT-2 inhibitor together with metformin fits this goal well. GLP-1 receptor agonists reduce appetite and slow stomach emptying, often leading to meaningful weight loss. SGLT-2 inhibitors promote urinary glucose excretion, which can also contribute to modest weight loss. Metformin, serving as a foundational therapy, is typically weight-neutral or can cause a small amount of weight loss and improves hepatic glucose production. If blood glucose remains above target after these agents, adding basal insulin can achieve better control, and when used carefully at low doses, it helps minimize additional weight gain.

Other approaches are less favorable for weight loss. Metformin alone may control glucose but doesn’t provide the additional weight-loss benefits of GLP-1 RAs or SGLT-2 inhibitors. Sulfonylureas and insulin tend to promote weight gain and carry higher risks of hypoglycemia, and thiazolidinediones are associated with weight gain and fluid retention, making them less ideal if weight loss is a goal.